CLL: Idelalisib based regimens

Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLLПодробнее

CLL: Chemotherapy and Ibrutinib based regimensПодробнее

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimenПодробнее

Idelalisib in Chronic Lymphocytic LeukemiaПодробнее

CLL: Long-term updates on ibrutinib and idelalisibПодробнее

Side-effect of idelalisib and its use in chronic lymphocytic leukemiaПодробнее

An unmet need in CLL: patients failing ibrutinib and idelalisibПодробнее

A nationwide population-based study on the incidence of infections in CLL and multiple myelomaПодробнее

Tirabrutinib with idelalisib or entospletinib +/- obinutuzumab in R/R CLLПодробнее

Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLLПодробнее

Dr. Kipps on Ibrutinib and Idelalisib For CLLПодробнее

Idelalisib for Previously Treated CLLПодробнее

The risk of infection for CLL patients receiving idelalisibПодробнее

OS after adjustment for crossover in a study of idelalisib with rituximab for relapsed CLLПодробнее

Understanding the Trial With Idelalisib and RituximabПодробнее

Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLLПодробнее

Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLLПодробнее

Second Interim Phase 3 Study of Idelalisib /Rituximab for Relapsed Chronic Lymphocytic LeukemiaПодробнее

Approaches to overcome side effects of idelalisib for follicular lymphomaПодробнее